The Lambert Initiative is researching the application of phytocannabinoids to assist in the treatment and management of chronic and neuropathic pain.
This research project will investigate the chronic pain that commonly occurs after spinal cord injury.
The first part of the study will compare brain images of individuals who develop chronic pain after spinal cord injury to those who do not. This will help determine underlying brain changes responsible for the chronic neuropathic pain. In the second part of the study, a randomised, double-blind placebo-controlled study will be used to investigate cannabidiol’s ability to reduce pain.
Chief Investigator: Professor Luke Henderson (Brain and Mind Centre, School of Medical Sciences, University of Sydney)
If you are interested in participating in this study, register your interest by contacting Professor Henderson by phone (02 9351 7063) or email (email@example.com).
Cannabis and THC have efficacy against neuropathic pain, however, this is hampered by their side effects. It has been suggested that co-administration with CBD might enhance the analgesic actions of THC and minimise its deleterious side effects. We examined the basis for this phytocannabinoid interaction in a mouse model of neuropathic pain.
Results: We found that THC and CBD reduced neuropathic pain. CBD had no adverse side effects. The 1:1 combination of THC and CBD synergistically reduced neuropathic pain with 100-fold greater efficacy than predicted from an additive interaction. THC also synergistically enhanced the efficacy of current first-line neuropathic pain treatments gabapentin and duloxetine.
This was a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney; the Kolling Institute; Royal North Shore Hospital; the Pain Management Research Institute at the University of Sydney, and the Northern Clinical School at the University of Sydney.